Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease

Molecular Brain

Volumn 7, Issue 1, 2014, Pages

  Ortolano, Saida ^a   Vieitez, Irene ^a   Agis Balboa, Roberto Carlos ^a   Spuch, Carlos ^a  

^a Hospital Do Rebullón   (Spain)

Author keywords

BDNF; Cerebral cortex; GABAergic neurons; Lafora disease; Laforin; Neurotrophin; NGF; p75NTR

Indexed keywords

ACTINS; AGING; ANIMALS; CASPASE 3; CELL COUNT; CELL NUCLEUS; CEREBRAL CORTEX; DENDRITES; DUAL-SPECIFICITY PHOSPHATASES; GABAERGIC NEURONS; INCLUSION BODIES; LAFORA DISEASE; LYSOSOMES; MICE; NERVE GROWTH FACTORS; PROTEIN TRANSPORT; PROTEOLYSIS; SUBCELLULAR FRACTIONS; SYNAPSES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893834550     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-7-7     Document Type: Article

References (69)

1. Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B. Chan EM, Andrade DM, Franceschetti S, Minassian B, Adv Neurol 2005 95 47 57 15508913
2. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. Ganesh S, Puri R, Singh S, Mittal S, Dubey D, J Hum Genet 2006 51 1 8 10.1007/s10038-005-0321-1 16311711 (Pubitemid 43162244)
3. Lafora progressive myoclonus epilepsy: recent insights into cell degeneration. Spuch C, Ortolano S, Navarro C, Recent Pat Endocr Metab Drug Discov 2012 6 99 107 10.2174/187221412800604617
4. Studies in myoclonus epilepsy (Lafora body form). Isolation and preliminary characterization of Lafora bodies in two cases. Yokoi S, Austin J, Witmer F, Sakai M, Arch Neurol 1968 19 15 33 10.1001/archneur.1968. 00480010033002 4175641
5. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, Dunham I, Gardner R, Fong CY, Carpenter S, Jardim L, Satishchandra P, Andermann E, Snead OC 3rd, Lopes-Cendes I, Tsui LC, Delgado-Escueta AV, Rouleau GA, Scherer SW, Nat Genet 1998 20 171 174 10.1038/2470 9771710 (Pubitemid 28455450)
6. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Serratosa JM, Gómez-Garre P, Gallardo ME, Anta B, de Bernabé DB, Lindhout D, Augustijn PB, Tassinari CA, Malafosse RM, Topcu M, Grid D, Dravet C, Berkovic SF, de Córdoba SR, Hum Mol Genet 1999 8 345 352 10.1093/hmg/8.2.345 9931343 (Pubitemid 29054277)
7. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G, Elia M, Ackerley CA, Jovic NJ, Bohlega S, Andermann E, Rouleau GA, Delgado-Escueta AV, Minassian BA, Scherer SW, Nat Genet 2003 35 125 127 10.1038/ng1238 12958597 (Pubitemid 37187629)
8. Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22. Chan EM, Bulman DE, Paterson AD, Turnbull J, Andermann E, Andermann F, Rouleau GA, Delgado-Escueta AV, Scherer SW, Minassian BA, J Med Genet 2003 40 671 675 10.1136/jmg.40.9.671 12960212 (Pubitemid 37100699)
9. Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Chan EM, Omer S, Ahmed M, Bridges LR, Bennett C, Scherer SW, Minassian BA, Neurology 2004 63 565 567 10.1212/01.WNL.0000133215. 65836.03 15304597 (Pubitemid 39031396)
10. Early-onset Lafora body disease. Turnbull J, Girard JM, Lohi H, Chan EM, Wang P, Tiberia E, Omer S, Ahmed M, Bennett C, Chakrabarty A, Tyagi A, Liu Y, Pencea N, Zhao X, Scherer SW, Ackerley CA, Minassian BA, Brain 2012 135 2684 2698 10.1093/brain/aws205 22961547
11. Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease. Valles-Ortega J, Duran J, Garcia-Rocha M, Bosch C, Saez I, Pujadas L, Serafin A, Cañas X, Soriano E, Delgado-García JM, Gruart A, Guinovart JJ, EMBO Mol Med 2011 3 667 681 10.1002/emmm.201100174 21882344
12. Targeted disruption of the Epm2a gene causes formation of lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Ganesh S, Delgado-Escueta AV, Sakamoto T, Avila MR, Machado-Salas J, Hoshii Y, Akagi T, Gomi H, Suzuki T, Amano K, Agarwala KL, Hasegawa Y, Bai DS, Ishihara T, Hashikawa T, Itohara S, Cornford EM, Niki H, Yamakawa K, Hum Mol Genet 2002 11 1251 1262 10.1093/hmg/11.11.1251 12019206 (Pubitemid 34555522)
13. Laforin, a protein with many faces: glucan phosphatase, adapter protein et alii. Gentry MS, Romá-Mateo C, Sanz P, FEBS J 2013 280 525 537 10.1111/j.1742-4658.2012.08549.x 22364389
14. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Tagliabracci VS, Turnbull J, Wang W, Girard JM, Zhao X, Skurat AV, Delgado-Escueta AV, Minassian BA, Depaoli-Roach AA, Roach PJ, Proc Natl Acad Sci USA 2007 104 19262 19266 10.1073/pnas.0707952104 18040046
15. Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. Tagliabracci VS, Girard JM, Segvich D, Meyer C, Turnbull J, Zhao X, Minassian BA, Depaoli-Roach AA, Roach PJ, J Biol Chem 2008 283 33816 33825 10.1074/jbc.M807428200 18852261
16. Glycogen and its metabolism: some new developments and old themes. Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS, Biochem J 2012 441 763 787 10.1042/BJ20111416 22248338
17. Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Lohi H, Ianzano L, Zhao XC, Chan EM, Turnbull J, Scherer SW, Ackerley CA, Minassian BA, Hum Mol Genet 2005 14 2727 2736 10.1093/hmg/ddi306 16115820 (Pubitemid 41300645)
18. Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway. Solaz-Fuster MC, Gimeno-Alcañiz JV, Ros S, Fernandez-Sanchez ME, Garcia-Fojeda B, Criado Garcia O, Vilchez D, Dominguez J, Garcia-Rocha M, Sanchez-Piris M, Aguado C, Knecht E, Serratosa J, Guinovart JJ, Sanz P, Rodriguez de Córdoba S, Hum Mol Genet 2008 17 667 678 18029386 (Pubitemid 351292256)
19. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Chan EM, Ackerley CA, Lohi H, Ianzano L, Cortez MA, Shannon P, Scherer SW, Minassian BA, Hum Mol Genet 2004 13 1117 1129 10.1093/hmg/ddh130 15102711 (Pubitemid 38786994)
20. Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Criado O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, San Millán B, Heredia M, Romá-Mateo C, Mouron S, Juana-López L, Domínguez M, Navarro C, Serratosa JM, Sanchez M, Sanz P, Bovolenta P, Knecht E, Rodriguez de Cordoba S, Hum Mol Genet 2012 21 1521 1533 10.1093/hmg/ddr590 22186026
21. PTG depletion removes lafora bodies and rescues the fatal epilepsy of lafora disease. Turnbull J, DePaoli-Roach AA, Zhao X, Cortez MA, Pencea N, Tiberia E, Piliguian M, Roach PJ, Wang P, Ackerley CA, Minassian BA, PLoS Genet 2011 7 1002037 10.1371/journal.pgen.1002037 21552327
22. Lafora disease: epidemiology, pathophysiology and management. Monaghan TS, Delanty N, CNS Drugs 2010 24 549 561 10.2165/11319250-000000000-00000 20527995
23. Are GAD65 and GAD67 associated with specific pools of GABA in brain? Martin DL, Barke KE, Perspect Dev Neurobiol 1998 5 119 129 9777630 (Pubitemid 28505490)
24. Cleavage of p75 neurotrophin receptor by -secretase and γ-secretase requires specific receptor domains. Zampieri N, Xu CF, Neubert TA, Chao MV, J Biol Chem 2005 280 14563 14571 10.1074/jbc.M412957200 15701642 (Pubitemid 40562799)
25. MAG induces regulated intramembrane proteolysis of the p75 neurotrophin receptor to inhibit neurite outgrowth. Domeniconi M, Zampieri N, Spencer T, Hilaire M, Mellado W, Chao MV, Filbin MT, Neuron 2005 46 849 855 10.1016/j.neuron.2005.05.029 15953414 (Pubitemid 40805346)
26. Ligand-independent signaling by disulfide-crosslinked dimers of the p75 neurotrophin receptor. Vilar M, Charalampopoulos I, Kenchappa RS, Reversi A, Klos-Applequist JM, Karaca E, Simi A, Spuch C, Choi S, Friedman WJ, Ericson J, Schiavo G, Carter BD, Ibáñez CF, J Cell Sci 2009 122 3351 3357 10.1242/jcs.055061 19706676
27. The p75 neurotrophin receptor localization in blood-CSF barrier: expression in choroid plexus epithelium. Spuch C, Carro E, BMC Neurosci 2011 12 39 10.1186/1471-2202-12-39 21569322
28. Lafora disease: a quantitative morphological and biochemical study of the cerebral cortex. Busard HL, Renier WO, Gabreels FJ, Jaspar HH, Slooff JL, Janssen AJ, Van Haelst UJ, Clin Neuropathol 1987 6 1 6 3032486 (Pubitemid 17019412)
29. Neocortex. Douglas R, Martin K, The Synaptic Organization of the Brain Oxford, UK: Oxford University Press, Shepherd GM, 4 1998 459 509
30. Sensorimotor cortex excitability in Unverricht-Lundborg disease and Lafora body disease. Canafoglia L, Ciano C, Panzica F, Scaioli V, Zucca C, Agazzi P, Visani E, Avanzini G, Franceschetti S, Neurology 2004 63 2309 2315 10.1212/01.WNL.0000147475.71345.AA 15623692 (Pubitemid 40024342)
31. Short and long interval cortical inhibition in patients with Unverricht-Lundborg and Lafora body disease. Canafoglia L, Ciano C, Visani E, Anversa P, Panzica F, Viri M, Gennaro E, Zara F, Madia F, Franceschetti S, Epilepsy Res 2010 89 232 237 10.1016/j.eplepsyres.2010.01.006 20117916
32. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davis SW, Proc Natl Acad Sci USA 2000 97 8093 8097 10.1073/pnas.110078997 10869421 (Pubitemid 30460778)
33. Ontogeny of Lafora bodies and neurocytoskeleton changes in laforin-deficient mice. Machado-Salas J, Avila-Costa MR, Guevara P, Guevara J, Durón RM, Bai D, Tanaka M, Yamakawa K, Delgado-Escueta AV, Exp Neurol 2012 236 131 140 10.1016/j.expneurol.2012.04.008 22542948
34. Cerebral blood flow and metabolism in Lafora disease. Tsuda H, Katsumi Y, Nakamura M, Ikeda A, Fukuyama H, Kimura J, Shibasaki H, Rinsho Shinkeigaku 1995 35 175 179 7781235
35. Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for lafora disease. Puri R, Suzuki T, Yamakawa K, Ganesh S, J Biol Chem 2009 284 22657 22663 10.1074/jbc.M109.009688 19542233
36. Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a Mouse model for Lafora disease. Puri R, Suzuki T, Yamakawa K, Ganesh S, Hum Mol Genet 2012 21 175 184 10.1093/hmg/ddr452 21965301
37. Astrocytes: biology and pathology. Sofroniew MV, Vinters HV, Acta Neuropathol 2010 119 7 35 10.1007/s00401-009-0619-8 20012068
38. Laforin, the most common protein mutated in Lafora disease, regulates autophagy. Aguado C, Sarkar S, Korolchuk VI, Criado O, Vernia S, Boya P, Sanz P, de Córdoba SR, Knecht E, Rubinsztein DC, Hum Mol Genet 2010 19 2867 2876 10.1093/hmg/ddq190 20453062
39. Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function. Minamide LS, Striegl AM, Boyle JA, Meberg PJ, Bamburg JR, Nat Cell Biol 2000 2 628 636 10.1038/35023579 10980704
40. Mechanism supressing glycogen synthesis in neurons and its demise progressive myoclobus epilepsy. Vilchez D, Ros S, Cifuentes D, Pujadas L, Vallès J, García-Fojeda B, Criado-García O, Fernández-Sánchez E, Medraño-Fernández I, Domínguez J, García-Rocha M, Soriano E, Rodríguez de Córdoba S, Guinovart JJ, Nat Neurosci 2007 10 1407 1413 10.1038/nn1998 17952067 (Pubitemid 350014686)
41. p53 in growth control and neoplasia. Gottlieb MT, Oren M, Biochim Biophys Acta 1996 1287 77 102 8672531 (Pubitemid 26189189)
42. p53: puzzle and paradigm. Ko JL, Prives C, Genes Dev 1996 10 1054 1072 10.1101/gad.10.9.1054 8654922 (Pubitemid 26152848)
43. Tissue-specific p53 expression in the nervous system. Tendler Y, Weisinger G, Coleman R, Diamond E, Lischinsky S, Kerner H, Rotter V, Zinder O, Brain Res Mol Brain Res 1999 72 40 46 10.1016/S0169-328X(99)00202-8 10521597 (Pubitemid 29474913)
44. Direct involvement of p53 in programmed cell death of oligodendrocytes. Eizenberg O, Faber-Elman A, Gotlieb E, Oren M, Rotter V, Schwartz M, EMBO J 1995 14 1136 1144 7720704
45. Neurotrophin receptors: old friends with new partners. Schecterson LC, Bothwell M, Dev Neurobiol 2010 70 332 338 20186712
46. Physiology of neurotrophins. Lewin GR, Barde YA, Annu Rev Neurosci 1996 19 289 317 10.1146/annurev.ne.19.030196.001445 8833445
47. Role of neurotrophins in synapse development and plasticity. Lu B, Figurov A, Rev Neurosci 1997 8 1 12 9402641 (Pubitemid 27354654)
48. BDNF-modulated spatial organization of Cajal-Retzius and GABAergic neurons in the marginal zone plays a role in the development of cortical organization. Alcantara S, Pozas E, Ibañez CF, Soriano E, Cereb Cortex 2006 16 487 499 16000651
49. BDNF promotes differentiation and maturation of adult-born neurons through GABAergic transmission. Waterhouse EG, An JJ, Orefice LL, Baydyuk M, Liao GY, Zheng K, Lu B, Xu B, J Neurosci 2012 32 14318 14330 10.1523/JNEUROSCI.0709-12.2012 23055503
50. BDNF and epilepsy: too much of a good thing? Binder DK, Croll SD, Gall CM, Scharfman HE, Trends Neurosci 2001 19 47 53 (Pubitemid 32332896)
51. BDNF and epilepsy-the bad could turn out to be good. Reibel S, Depaulis A, Larmet Y, Trends Neurosci 2001 24 318 319 10.1016/S0166-2236(00)01869-5 11421232 (Pubitemid 32455430)
52. Neurotrophins induce death of hippocampal neurons via the p75 receptor. Friedman WJ, J Neurosci 2000 20 6340 6346 10964939
53. Complete deletion of the neurotrophin receptor p75NTR leads to long-lasting increases in the number of basal forebrain cholinergic neurons. Naumann T, Casademunt E, Hollerbach E, Hofmann J, Dechant G, Frotscher M, Barde YA, J Neurosci 2002 22 2409 2418 11923404 (Pubitemid 37465788)
54. p75 neurotrophin receptor-mediated apoptosis in sympathetic neurons involves a biphasic activation of JNK and up-regulation of tumor necrosis factor alpha converting enzyme/ADAM17. Kenchappa RS, Tep C, Korade Z, Urra S, Bronfman FC, Yoon SO, Carter BD, J Biol Chem 2010 285 20358 20368 10.1074/jbc.M109. 082834 20421303
55. Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. Jung KM, Tan S, Landman N, Petrova K, Murray S, Lewis R, Kim PK, Kim DS, Ryu SH, Chao MV, Kim TW, J Biol Chem 2003 278 42161 42169 10.1074/jbc.M306028200 12913006 (Pubitemid 37310483)
56. Proteolytic processing of the p75 neurotrophin receptor and two homologues generates C-terminal fragments with signaling capability. Kanning KC, Hudson M, Amieux PS, Wiley JC, Bothwell M, Schecterson LC, J Neurosci 2003 23 5425 5436 12843241 (Pubitemid 36807816)
57. A RIP tide in neuronal signal transduction. Ebinu JO, Yankner BA, Neuron 2002 34 499 502 10.1016/S0896-6273(02)00704-3 12062033 (Pubitemid 34628747)
58. Corpora-amylacea and the family of polyglucosan diseases. Cavanagh JB, Brain Res Brain Res Rev 1999 29 265 295 10.1016/S0165-0173(99)00003-X 10209236 (Pubitemid 29191343)
59. A novel role for PTEN in the inhibition of neurite outgrowth by muelin-associated glycoprotein in cortical neurons. Perdigoto AL, Chaudhry N, Barnes GN, Filbin MT, Carter BD, Mol Cell Neurosci 2011 46 235 244 10.1016/j.mcn.2010.09.006 20869442
60. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin. DePaoli-Roach AA, Tagliabracci VS, Segvich DM, Meyer CM, Irimia JM, Roach PJ, J Biol Chem 2010 285 25372 25381 10.1074/jbc.M110.148668 20538597
61. Lafora progressive myoclonus epilepsy: glycogen storage disease vs neurodegenerative disease. Delgado-Escueta AV, Neurology 2012 79 21 22 10.1212/WNL.0b013e31825dcea6 22622859
62. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, Mills GB, Proc Natl Acad Sci USA 2000 97 11960 11965 10.1073/pnas.220413597 11035810
63. A positive feedback loop between glycogen synthase kinase 3beta and protein phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain neurons. Szatmari E, Habas A, Yang P, Zheng JJ, Hagg T, Hetman M, J Biol Chem 2005 280 37526 37535 10.1074/jbc.M502699200 16155008 (Pubitemid 41642361)
64. Polyglucosan bodies in brain tissue: a systematic study. Busard HL, Span JP, Renkawek K, Renier WO, Gabreëls FJ, Slooff JL, Hof MA V't, Clin Neuropathol 1994 13 60 63 8205727 (Pubitemid 24078629)
65. Lafora disease: insights into neurodegeneration from plant metabolism. Gentry MS, Dixon JE, Worby CA, Trends Biochem Sci 2009 34 628 639 10.1016/j.tibs.2009.08.002 19818631
66. Deleterious effects of neuronal accumulation of glycogen in flies and mice. Duran J, Tevy MF, Garcia-Rocha M, Calbó J, Milán M, Guinovart JJ, EMBO Mol Med 2012 4 719 729 10.1002/emmm.201200241 22549942
67. The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease. Spuch C, Antequera D, Portero A, Orive G, Hernández RM, Molina JA, Bermejo-Pareja F, Pedraz JL, Carro E, Biomaterials 2010 31 5608 5618 10.1016/j.biomaterials. 2010.03.042 20430437
68. Mesenchymal and neuronal cell expression of the p75 neurotrophin receptor gene occur by different mechanisms. Huber LJ, Chao MV, Dev Biol 1995 167 227 238 10.1006/dbio.1995.1019 7851645
69. A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6 J Mouse. Baquet ZC, Williams D, Brody J, Smeyne RJ, Neuroscience 2009 161 1082 1090 10.1016/j.neuroscience.2009.04.031 19376196